
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Zusammenfassung
This phase 3 randomized, double-blind, placebo-controlled trial evaluated MDMA-assisted therapy for severe PTSD. After three sessions, 67% of participants no longer met diagnostic criteria for PTSD, compared to 32% in the placebo group.
Schlüsselwörter
MDMAPTSDphase 3clinical trialpsychedelic therapy
Klinische Forschung
